User login
Anil Rustgi, MD, AGAF, and Raymond DuBois, MD, PhD, AGAF, were elected to the National Academy of Medicine, considered one of the highest honors in the fields of health and medicine and recognizes individuals who have demonstrated outstanding professional achievement and commitment to service.
Share your congratulations with both Dr. Rustgi and Dr. DuBois on the AGA Community.
Dr. Rustgi is recognized for illuminating the importance of GI cancers, genomics, and genetics and demonstrating that p120-catenin, part of the adherens junctions, is a tumor suppressor gene in cancers and the first to link p120-catenin to mesenchymal-epithelial transition (MET) in tumor metastasis, advancing therapeutic opportunities.
Dr. Rustgi is Irving Professor of Medicine and director of the Herbert Irving Comprehensive Cancer Center, and associate dean of oncology, department of medicine, Vagelos College of Physicians and Surgeons at Columbia University, New York.
Dr. DuBois is recognized for discovering the critical and mechanistic role of prostaglandins (PGs)/cyclooxygenase in colon cancer and its malignant progression, elucidating the role of PGs in the tumor microenvironment, and spearheading the now common use of drugs for human cancer prevention that target the PG pathway, like aspirin and other NSAIDs.
Dr. DuBois is dean of the College of Medicine, and professor of biochemistry and medicine at The Medical University of South Carolina, Charleston.
Anil Rustgi, MD, AGAF, and Raymond DuBois, MD, PhD, AGAF, were elected to the National Academy of Medicine, considered one of the highest honors in the fields of health and medicine and recognizes individuals who have demonstrated outstanding professional achievement and commitment to service.
Share your congratulations with both Dr. Rustgi and Dr. DuBois on the AGA Community.
Dr. Rustgi is recognized for illuminating the importance of GI cancers, genomics, and genetics and demonstrating that p120-catenin, part of the adherens junctions, is a tumor suppressor gene in cancers and the first to link p120-catenin to mesenchymal-epithelial transition (MET) in tumor metastasis, advancing therapeutic opportunities.
Dr. Rustgi is Irving Professor of Medicine and director of the Herbert Irving Comprehensive Cancer Center, and associate dean of oncology, department of medicine, Vagelos College of Physicians and Surgeons at Columbia University, New York.
Dr. DuBois is recognized for discovering the critical and mechanistic role of prostaglandins (PGs)/cyclooxygenase in colon cancer and its malignant progression, elucidating the role of PGs in the tumor microenvironment, and spearheading the now common use of drugs for human cancer prevention that target the PG pathway, like aspirin and other NSAIDs.
Dr. DuBois is dean of the College of Medicine, and professor of biochemistry and medicine at The Medical University of South Carolina, Charleston.
Anil Rustgi, MD, AGAF, and Raymond DuBois, MD, PhD, AGAF, were elected to the National Academy of Medicine, considered one of the highest honors in the fields of health and medicine and recognizes individuals who have demonstrated outstanding professional achievement and commitment to service.
Share your congratulations with both Dr. Rustgi and Dr. DuBois on the AGA Community.
Dr. Rustgi is recognized for illuminating the importance of GI cancers, genomics, and genetics and demonstrating that p120-catenin, part of the adherens junctions, is a tumor suppressor gene in cancers and the first to link p120-catenin to mesenchymal-epithelial transition (MET) in tumor metastasis, advancing therapeutic opportunities.
Dr. Rustgi is Irving Professor of Medicine and director of the Herbert Irving Comprehensive Cancer Center, and associate dean of oncology, department of medicine, Vagelos College of Physicians and Surgeons at Columbia University, New York.
Dr. DuBois is recognized for discovering the critical and mechanistic role of prostaglandins (PGs)/cyclooxygenase in colon cancer and its malignant progression, elucidating the role of PGs in the tumor microenvironment, and spearheading the now common use of drugs for human cancer prevention that target the PG pathway, like aspirin and other NSAIDs.
Dr. DuBois is dean of the College of Medicine, and professor of biochemistry and medicine at The Medical University of South Carolina, Charleston.